This Week in Cardiology — Jun 8, 2026

Welcome to This Week in Cardiology. This week we're covering 9 notable papers spanning major advances in cardio-renal protection, new strategies for secondary prevention in atherosclerotic disease, and fresh insights into the lifelong management of s… This week's papers: 1. Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants. — Nature medicine 2026 2. Survivors of Cyanotic Congenital Heart Disease: A Review. — JAMA 2026 3. Structured Telehealth Community Health Worker-Clinician Feedback and Diabetes Outcomes: A Randomized Clinical Trial. — JAMA internal medicine 2026 4. Activation of HIF2 in Cardiac Vasculature Leads to Arterial Remodeling, Dilation, Thrombosis, and Inflammation, Recapitulating Cardiac Involvement in Kawasaki… — Circulation 2026 5. Prevalence and prognostic role of untreated moderate-to-severe tricuspid regurgitation: a systematic review and meta-analysis. — European journal of heart failure 2026 6. Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY). — Lancet (London, England) 2026 7. P2Y12 inhibitor monotherapy after abbreviated dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis. — European heart journal 2026 8. Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REA… — European heart journal 2026 9. Finerenone in Persons with Chronic Kidney Disease without Diabetes. — The New England journal of medicine 2026 Listen at https://audioscholar.cc/episode/bpmgg9pfsu